Treatment of Kappa and Lambda Light Chain Multiple Myeloma
For newly diagnosed light chain multiple myeloma, use a monoclonal antibody-based triplet or quadruplet regimen combining daratumumab with a proteasome inhibitor (bortezomib or carfilzomib) and an immunomodulatory drug (lenalidomide), with dexamethasone as the backbone. 1
Initial Treatment Strategy
The treatment approach for light chain myeloma does not fundamentally differ from intact immunoglobulin myeloma, but requires heightened attention to renal complications since light chain cast nephropathy frequently causes severe kidney injury.
Frontline Therapy Selection
For transplant-eligible, transplant-deferred, and fit transplant-ineligible patients under 80 years:
- Preferred regimen: Daratumumab + Lenalidomide + Bortezomib/Carfilzomib + Dexamethasone as induction 1
- This anti-CD38 monoclonal antibody-based quadruplet provides the deepest responses and longest progression-free survival
- The BPV regimen (bendamustine, prednisone, bortezomib) showed 96% response rate in light chain myeloma with rapid light chain reduction after just 1-2 cycles, making it particularly valuable when rapid disease control is needed for renal protection 2
Critical Considerations for Light Chain Disease
Renal function is paramount. In light chain myeloma, 56% of patients present with severe renal dysfunction or dialysis-dependence 2. The rapid reduction of circulating light chains is essential to prevent irreversible kidney damage:
- Light chains decrease most rapidly with proteasome inhibitor-based regimens
- Median time to best response: after cycle 1 in 36% and after cycle 2 in additional 48% of patients 2
- Renal function improvement occurs in 67% of patients with at least moderate renal failure when treated aggressively 2
Relapsed/Refractory Disease Management
After 1-3 Prior Therapies
For bortezomib and/or lenalidomide-refractory disease, daratumumab + carfilzomib + dexamethasone is the preferred regimen 1. This combination achieved:
- 84% overall response rate
- Median PFS of 28.6 months vs 15.2 months without daratumumab (HR 0.59, P<0.0001) 1
A monoclonal antibody-based triplet combining an immunomodulatory drug and/or proteasome inhibitor should be standard 3. The hierarchy based on network meta-analysis:
- Daratumumab + lenalidomide + dexamethasone (best ranking)
- Carfilzomib + lenalidomide + dexamethasone
- Elotuzumab + lenalidomide + dexamethasone 3
Timing Considerations
- If relapse occurs >6 months after completing initial therapy, retreatment with the same regimen is acceptable 1
- If relapse occurs during therapy or within 1 year, the disease is considered refractory and requires a different mechanistic approach 3
- For patients progressing on lenalidomide maintenance, switch to bortezomib + monoclonal antibody 3
- For bortezomib-refractory cases, use lenalidomide + monoclonal antibody 3
Early Relapse (1-3 Prior Lines)
CAR T-cell therapy targeting BCMA, specifically ciltacabtagene autoleucel (cilta-cel), has demonstrated superiority over standard regimens and should be prioritized when clinically feasible 4. This represents the most efficacious option currently available, though parkinsomism is a unique toxicity requiring monitoring.
Alternative options include:
- Belantamab mafadotin-based triplets (particularly effective in lenalidomide and anti-CD38 refractory patients, though ocular toxicity requires ophthalmologic monitoring) 4
- Anti-CD38 + carfilzomib-based triplets remain essential for patients not refractory to anti-CD38 4
Late Relapse (≥4 Prior Lines)
Bispecific antibodies should be deployed after CAR T-cell therapy, as sequential efficacy is compromised in the reverse sequence 4. Options include:
BCMA-targeting bispecifics:
- Teclistamab
- Elranatamab
- Linvoseltamab
GPRC5D-targeting:
- Talquetamab (distinct toxicity profile from BCMA-targeting agents) 4
For BCMA and GPRC5D-refractory disease:
- FcRH5-targeting bispecific (cevostamab)
- BCL2 inhibitors specifically for t(11;14)-positive disease
- Novel trispecific antibodies (BCMA×CD38; BCMA×GPRC5D) 4
Transplant Considerations
- Autologous stem cell transplant should be offered to eligible patients who didn't receive it as initial therapy 3
- Repeat transplant may be considered if PFS after first transplant was ≥18 months 3
- For patients who had durable response with initial transplant, second transplantation can be considered at relapse 1
Adjunctive Renal Support
For dialysis-dependent patients with light chain myeloma, medium cutoff (MCO) membrane hemodialysis effectively removes free light chains 5:
- Reduces kappa FLC by 70% and lambda FLC by 37% per session
- 57% of patients (34/60) achieved dialysis independence after 1 year
- Less costly and technically simpler than high cutoff dialysis 5
- Kappa chains are more efficiently removed than lambda chains due to size differences (22.5 kDa vs 45 kDa) 6
Common Pitfalls
- Delaying treatment while awaiting "perfect" renal recovery - Start chemotherapy immediately as light chain reduction is time-sensitive for kidney salvage
- Using conventional dialysis alone - Standard dialysis is inadequate for light chain removal; MCO or HCO membranes are required 6
- Treating light chain myeloma less aggressively - These patients require equally intensive therapy as intact immunoglobulin myeloma, with added urgency for renal protection
- Sequencing CAR T after bispecific antibodies - This compromises CAR T efficacy; prioritize CAR T first when both are options 4